...
search icon
ghrs-img

GH Research PLC, Common Stock

GHRS

NMQ

$9.5

+$0.69

(7.83%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$494.27M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
214.55K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.74
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6 L
$14.99 H
$9.5

About GH Research PLC, Common Stock

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGHRSSectorS&P500
1-Week Return5.67%3.54%-0.58%
1-Month Return26.67%7.51%1.89%
3-Month Return17.87%-0.85%3.24%
6-Month Return-22.45%-1.67%10.09%
1-Year Return28.21%5.2%22.09%
3-Year Return-39.91%13.08%35.68%
5-Year Return-50.65%44.4%83.47%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue--19.00K47.00K315.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":6.03,"profit":true},{"date":"2022-12-31","value":14.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit--(19.00K)(47.00K)(315.00K)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-1900000,"profit":false},{"date":"2022-12-31","value":-4700000,"profit":false},{"date":"2023-12-31","value":-31500000,"profit":false}]
Gross Margin-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses310.00K446.00K15.10M30.55M41.22M[{"date":"2019-12-31","value":0.75,"profit":true},{"date":"2020-12-31","value":1.08,"profit":true},{"date":"2021-12-31","value":36.63,"profit":true},{"date":"2022-12-31","value":74.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(310.00K)(446.00K)(15.10M)(30.55M)(41.22M)[{"date":"2019-12-31","value":-31000000,"profit":false},{"date":"2020-12-31","value":-44600000,"profit":false},{"date":"2021-12-31","value":-1510000000,"profit":false},{"date":"2022-12-31","value":-3055400000,"profit":false},{"date":"2023-12-31","value":-4122200000,"profit":false}]
Total Non-Operating Income/Expense--5.89M9.02M13.89M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":42.4,"profit":true},{"date":"2022-12-31","value":64.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(310.00K)(446.00K)(9.20M)(22.46M)(35.59M)[{"date":"2019-12-31","value":-31000000,"profit":false},{"date":"2020-12-31","value":-44600000,"profit":false},{"date":"2021-12-31","value":-920200000,"profit":false},{"date":"2022-12-31","value":-2245600000,"profit":false},{"date":"2023-12-31","value":-3558700000,"profit":false}]
Income Taxes(310.00)(205.30K)9.00K(15.32M)(1.00)[{"date":"2019-12-31","value":-3.44,"profit":false},{"date":"2020-12-31","value":-2281.08,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-170233.33,"profit":false},{"date":"2023-12-31","value":-0.01,"profit":false}]
Income After Taxes(309.69K)(240.70K)(9.21M)(7.13M)(35.59M)[{"date":"2019-12-31","value":-30969000,"profit":false},{"date":"2020-12-31","value":-24070300,"profit":false},{"date":"2021-12-31","value":-921100000,"profit":false},{"date":"2022-12-31","value":-713500000,"profit":false},{"date":"2023-12-31","value":-3558699900,"profit":false}]
Income From Continuous Operations(310.00K)(446.00K)(9.20M)(22.46M)(35.59M)[{"date":"2019-12-31","value":-31000000,"profit":false},{"date":"2020-12-31","value":-44600000,"profit":false},{"date":"2021-12-31","value":-920200000,"profit":false},{"date":"2022-12-31","value":-2245600000,"profit":false},{"date":"2023-12-31","value":-3558700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(310.00K)(446.00K)(9.21M)(7.13M)(35.59M)[{"date":"2019-12-31","value":-31000000,"profit":false},{"date":"2020-12-31","value":-44600000,"profit":false},{"date":"2021-12-31","value":-921100000,"profit":false},{"date":"2022-12-31","value":-713500000,"profit":false},{"date":"2023-12-31","value":-3558700000,"profit":false}]
EPS (Diluted)(0.00)(0.02)(0.19)(0.43)(0.68)[{"date":"2019-12-31","value":-0.03,"profit":false},{"date":"2020-12-31","value":-1.51,"profit":false},{"date":"2021-12-31","value":-19,"profit":false},{"date":"2022-12-31","value":-43,"profit":false},{"date":"2023-12-31","value":-68,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GHRS
Cash Ratio 15.33
Current Ratio 15.83

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GHRS
ROA (LTM) -12.74%
ROE (LTM) -16.20%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GHRS
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GHRS
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.43
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is GH Research PLC share price today?

GH Research PLC (GHRS) share price today is $9.5

Can Indians buy GH Research PLC shares?

Yes, Indians can buy shares of GH Research PLC (GHRS) on Vested. To buy GH Research PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GHRS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of GH Research PLC be purchased?

Yes, you can purchase fractional shares of GH Research PLC (GHRS) via the Vested app. You can start investing in GH Research PLC (GHRS) with a minimum investment of $1.

How to invest in GH Research PLC shares from India?

You can invest in shares of GH Research PLC (GHRS) via Vested in three simple steps:

  • Click on Sign Up or Invest in GHRS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in GH Research PLC shares
What is GH Research PLC 52-week high and low stock price?

The 52-week high price of GH Research PLC (GHRS) is $14.99. The 52-week low price of GH Research PLC (GHRS) is $6.

What is GH Research PLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of GH Research PLC (GHRS) is 2.43

What is the Market Cap of GH Research PLC?

The market capitalization of GH Research PLC (GHRS) is $494.27M

What is GH Research PLC’s stock symbol?

The stock symbol (or ticker) of GH Research PLC is GHRS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top